First Patient Dosed in Orelabrutinib Phase III SLE Trial
Orelabrutinib posted a 57.1% SRI-4 response at Week 48 in Phase IIb versus 34.4% on placebo (p
Noted Annovis Alzheimer’s Trial Results Published in Nature
A 12-week Phase 2/3 study in 351 patients with mild to moderate Alzheimer’s disease reported statistically significant, dose-dependent improvements...
Five Approvals, Nine Expansions: What the EMA’s April CHMP Meeting Reveals About Where Global Drug Development Is Heading
EMA's CHMP recommended 5 new medicines and 9 indication expansions in its April 20–23 meeting — here's what the...
The Cognitive Penalty of ECT Has Always Been Its Ceiling — MST Just Removed It
CREST–MST in Lancet Psychiatry shows magnetic seizure therapy matches ECT remission rates with superior cognitive safety—reshaping convulsive therapy trial…
Biomea’s Icovamenib Shows Lasting C-Peptide Gains in T1D
In an open-label Phase 2 study of adults with Stage 3 type 1 diabetes, 12 weeks of the menin...
Intellia Announces Proposed Public Offering of Common Stock
Intellia Therapeutics launched a $150 million underwritten public offering of common stock, with a 30-day option for underwriters to...
Bioxodes’ BIOX-101 Shows Breakthrough ICH Trial Results
Final results from BIRCH, a 23-patient multicenter, randomized, open-label Phase 2a trial in spontaneous intracerebral hemorrhage, met the primary...
Structure to Present New Diabetes Combination Data at ADA
Structure Therapeutics will take an oral small-molecule GLP-1 receptor agonist into the ADA spotlight with Phase 2b ACCESS data...
FDA Fast Tracks Scancell’s Melanoma Drug After Phase 2 Data
Progression-free survival reached 77% at 20 months in the target HLA-selected population of Scancell’s Phase 2 SCOPE trial when...
ERAS-0015 Shows Surging Promise in KRAS Mutant Tumors
Unconfirmed overall response rates from early Phase 1 readouts of ERAS-0015, a once-daily oral pan-RAS molecular glue, were 62%...